Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 1 of 1 for:    GSK 213500
Previous Study | Return to List | Next Study

A Study to Evaluate Efficacy and Safety of Cabotegravir (CAB) Long Acting (LA) Plus (+) Rilpivirine (RPV) LA Versus BIKTARVY® (BIK) in Participants With Human Immunodeficiency Virus (HIV)-1 Who Are Virologically Suppressed (SOLAR)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04542070
Recruitment Status : Recruiting
First Posted : September 9, 2020
Last Update Posted : January 27, 2021
Sponsor:
Collaborator:
Janssen, LP
Information provided by (Responsible Party):
ViiV Healthcare

Brief Summary:

Human immunodeficiency virus (HIV)/Acquired Immunodeficiency Syndrome (AIDS) is a worldwide epidemic that continues to grow significantly causing new infections and related deaths per year. Chronic HIV infection in adults continues to be characterized by increased development and transmission of resistant virus and issues associated with long-term toxicity of antiretroviral therapy (ART). The current paradigm in the treatment of HIV involves life-long therapy with multiple antiretrovirals (ARVs). This dependency on medical therapy requires a need for continuous improvement on the durability, tolerability and convenience of all antiretroviral classes. This is a Phase IIIb, randomized, open-label, active-controlled, multicenter, parallel-group, non-inferiority study (SOLAR: Switch Onto Long Acting Regimen). It is designed to assess the antiviral activity and safety of a two-drug regimen of CAB LA + RPV LA administered every 2 months (Q2M) compared with maintenance of BIK. Approximately 654 adult HIV-1 infected participants who are on the stable ARV regimen BIK will be randomized in a 2:1 ratio to either be switched to the CAB LA + RPV LA regimen or continue BIK through 12 months. The study will continue with an Extension Phase after Month 12 Oral Lead-In (OLI) and BIK/Month 11 Direct to Injection (D2I).

BIKTARVY is a registered trademark of Gilead Sciences.


Condition or disease Intervention/treatment Phase
HIV Infections Drug: Cabotegravir Tablets Drug: Cabotegravir Injectable Suspension (CAB LA) Drug: Rilpivirine Tablets Drug: Rilpivirine Injectable Suspension (RPV LA) Drug: BIKTARVY Tablets (BIK) Phase 3

Expanded Access : An investigational treatment associated with this study is available outside the clinical trial.   More info ...

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 654 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Intervention Model Description: A randomized, open-label, active-controlled, multicenter, parallel-group, non-inferiority study.
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase IIIb, Randomized, Multicenter, Active-controlled, Parallel-group, Non-inferiority, Open-label Study Evaluating the Efficacy, Safety, and Tolerability of Switching to Long-acting Cabotegravir Plus Long-acting Rilpivirine Administered Every Two Months From a Bictegravir/Emtricitabine/Tenofovir Alafenamide Single Tablet Regimen in HIV-1 Infected Adults Who Are Virologically Suppressed
Actual Study Start Date : November 9, 2020
Estimated Primary Completion Date : March 31, 2022
Estimated Study Completion Date : March 1, 2023

Resource links provided by the National Library of Medicine

MedlinePlus related topics: HIV/AIDS
Drug Information available for: Rilpivirine

Arm Intervention/treatment
Experimental: Participants receiving CAB LA + RPV LA regimen
Participants will be offered the option to start with a month long oral lead in or to start long acting intramuscular injections (OLI or D2I). On Day 1, participants who choose to participate in OLI will be administered CAB 30 milligrams (mg) + RPV 25 mg once daily orally for one month. At the Month 1 visit, last dose of oral CAB + RPV will be given followed by the first CAB LA 600 mg + RPV LA 900 mg intramuscular (IM) injection (within 2 hours of the final oral dose). The second IM injection with CAB LA 600 mg and RPV LA 900 mg will be administered at Month 2 followed by the same Q2M until Month 12. In D2I, at Day 1, eligible participants will receive the first injection of CAB LA 600 mg + RPV LA 900 mg as initial loading dose. The second and third injections (CAB LA 600 mg + RPV LA 900 mg) will be administered at Month 1 and Month 3 followed by the same Q2M until Month 11.
Drug: Cabotegravir Tablets
CAB tablets will be available as white to almost white oval shaped film coated tablets of 30 mg for oral administration.

Drug: Cabotegravir Injectable Suspension (CAB LA)
CAB LA will be available as sterile white to slightly pink suspension for injection in 200 mg/milliliters (mL) of GSK1265744 for administration as IM injection.

Drug: Rilpivirine Tablets
RPV tablets will be available as off-white, round, biconvex, film-coated tablets of 25 mg for oral administration. Each tablet contains 27.5 mg of Rilpivirine hydrochloride, which is equivalent to 25 mg of RPV.

Drug: Rilpivirine Injectable Suspension (RPV LA)
RPV LA will be available as a sterile white suspension containing 300 mg/mL of RPV to be administered as an IM injection.

Active Comparator: Participants receiving BIK
Participants will receive BIK, that is a combination of Bictegravir (BIC) 50 mg + Emtricitabine (FTC) 200 mg + Tenofovir alafenamide (TAF) 25 mg orally, administered once daily until Month 12.
Drug: BIKTARVY Tablets (BIK)
BIK will be available as purplish brown, capsule-shaped, film-coated tablet. It will be a three-drug fixed dose combination product containing 50 mg of BIC, 200 mg of FTC, and 25 mg of TAF for oral administration.




Primary Outcome Measures :
  1. Percentage of participants with plasma human immunodeficiency virus (HIV)-1 ribonucleic acid (RNA) greater than or equal to (>=) 50 copies per mL (c/mL) - OLI [ Time Frame: At Month 12 ]
    Participants with plasma HIV-1 RNA >=50 c/mL per Food and Drug Administration (FDA) snapshot algorithm will be assessed.

  2. Percentage of participants with plasma HIV-1 RNA >=50 c/mL - D2I [ Time Frame: At Month 11 ]
    Participants with plasma HIV-1 RNA >=50 c/mL per FDA snapshot algorithm will be assessed.

  3. Percentage of participants with plasma HIV-1 RNA >=50 c/mL - BIK [ Time Frame: At Month 12 ]
    Participants with plasma HIV-1 RNA >=50 c/mL per FDA snapshot algorithm will be assessed.


Secondary Outcome Measures :
  1. Percentage of participants with plasma HIV-1 RNA less than (<)50 c/mL - OLI [ Time Frame: At Months 6 and 12 ]
    Participants with plasma HIV-1 RNA <50 c/mL per FDA snapshot algorithm will be assessed.

  2. Percentage of participants with plasma HIV-1 RNA <50 c/mL - D2I [ Time Frame: At Months 5 and 11 ]
    Participants with plasma HIV-1 RNA <50 c/mL per FDA snapshot algorithm will be assessed.

  3. Percentage of participants with plasma HIV-1 RNA <50 c/mL - BIK [ Time Frame: At Months 6 and 12 ]
    Participants with plasma HIV-1 RNA <50 c/mL per FDA snapshot algorithm will be assessed.

  4. Percentage of participants with protocol-defined confirmed virologic failure (CVF) - OLI [ Time Frame: Up to Month 12 ]
    CVF is defined as rebound as indicated by two consecutive plasma HIV-1 RNA levels >=200 c/mL after prior suppression to <200 c/mL.

  5. Percentage of participants with protocol-defined CVF - D2I [ Time Frame: Up to Month 11 ]
    CVF is defined as rebound as indicated by two consecutive plasma HIV-1 RNA levels >=200 c/mL after prior suppression to <200 c/mL.

  6. Percentage of participants with protocol-defined CVF - BIK [ Time Frame: Up to Month 12 ]
    CVF is defined as rebound as indicated by two consecutive plasma HIV-1 RNA levels >=200 c/mL after prior suppression to <200 c/mL.

  7. Percentage of participants with HIV-RNA >= 50 c/mL - OLI [ Time Frame: At Month 6 ]
    Participants with plasma HIV-1 RNA >=50 c/mL will be assessed per FDA snapshot algorithm.

  8. Percentage of participants with HIV-RNA >= 50 c/mL - D2I [ Time Frame: At Month 5 ]
    Participants with plasma HIV-1 RNA >=50 c/mL will be assessed per FDA snapshot algorithm.

  9. Percentage of participants with HIV-RNA >= 50 c/mL - BIK [ Time Frame: At Month 6 ]
    Participants with plasma HIV-1 RNA >=50 c/mL will be assessed per FDA snapshot algorithm.

  10. Absolute values of HIV viral load - OLI [ Time Frame: At Months 6 and 12 ]
    Absolute values of HIV viral load will be assessed.

  11. Absolute values of HIV viral load - D2I [ Time Frame: At Months 5 and 11 ]
    Absolute values of HIV viral load will be assessed.

  12. Absolute values of HIV viral load - BIK [ Time Frame: At Months 6 and 12 ]
    Absolute values of HIV viral load will be assessed.

  13. Change from Baseline in HIV viral load (c/mL) - OLI [ Time Frame: Baseline (Day 1) and at Months 6 and 12 ]
    Change from Baseline in HIV viral load will be assessed.

  14. Change from Baseline in HIV viral load (c/mL) - D2I [ Time Frame: Baseline (Day 1) and at Months 5 and 11 ]
    Change from Baseline in HIV viral load will be assessed.

  15. Change from Baseline in HIV viral load (c/mL) - BIK [ Time Frame: Baseline (Day 1) and at Months 6 and 12 ]
    Change from Baseline in HIV viral load will be assessed.

  16. Absolute values of cluster of differentiation 4 plus (CD4+) cell counts - OLI [ Time Frame: At Months 6 and 12 ]
    Absolute values of CD4+ cell counts will be assessed.

  17. Absolute values of CD4+ cell counts - D2I [ Time Frame: At Months 5 and 11 ]
    Absolute values of CD4+ cell counts will be assessed.

  18. Absolute values of CD4+ cell counts - BIK [ Time Frame: At Months 6 and 12 ]
    Absolute values of CD4+ cell counts will be assessed.

  19. Change from Baseline in CD4+ cell counts (Cells per cubic millimeters [cells/mm^3]) - OLI [ Time Frame: Baseline (Day 1) and at Months 6 and 12 ]
    Change from Baseline in CD4+ cell will be assessed.

  20. Change from Baseline in CD4+ cell counts (cells/mm^3) - D2I [ Time Frame: Baseline (Day 1) and at Months 5 and 11 ]
    Change from Baseline in CD4+ cell will be assessed.

  21. Change from Baseline in CD4+ cell counts (cells/mm^3) - BIK [ Time Frame: Baseline (Day 1) and at Months 6 and 12 ]
    Change from Baseline in CD4+ cell will be assessed.

  22. Number of participants with treatment-emergent phenotypic resistance - OLI [ Time Frame: Up to Month 12 ]
    Plasma samples will be collected from participants experiencing protocol-defined CVF for assessing treatment-emergent phenotypic resistance to CAB, RPV, BIC, FTC, and TAF.

  23. Number of participants with treatment-emergent phenotypic resistance - D2I [ Time Frame: Up to Month 11 ]
    Plasma samples will be collected from participants experiencing protocol-defined CVF for assessing treatment-emergent phenotypic resistance to CAB, RPV, BIC, FTC, and TAF.

  24. Number of participants with treatment-emergent phenotypic resistance - BIK [ Time Frame: Up to Month 12 ]
    Plasma samples will be collected from participants experiencing protocol-defined CVF for assessing treatment-emergent phenotypic resistance to CAB, RPV, BIC, FTC, and TAF.

  25. Number of participants with treatment-emergent genotypic resistance - OLI [ Time Frame: Up to Month 12 ]
    Plasma samples will be collected from participants experiencing protocol-defined CVF for assessing treatment-emergent genotypic resistance to CAB, RPV, BIC, FTC, and TAF.

  26. Number of participants with treatment-emergent genotypic resistance - D2I [ Time Frame: Up to Month 11 ]
    Plasma samples will be collected from participants experiencing protocol-defined CVF for assessing treatment-emergent genotypic resistance to CAB, RPV, BIC, FTC, and TAF.

  27. Number of participants with treatment-emergent genotypic resistance - BIK [ Time Frame: Up to Month 12 ]
    Plasma samples will be collected from participants experiencing protocol-defined CVF for assessing treatment-emergent genotypic resistance to CAB, RPV, BIC, FTC, and TAF.

  28. Number of participants with abnormal renal and bone biomarkers - OLI [ Time Frame: At Months 6 and 12 ]
    Blood and urine samples will be collected over time to assess renal and bone biomarkers.

  29. Number of participants with abnormal renal and bone biomarkers - D2I [ Time Frame: At Months 5 and 11 ]
    Blood and urine samples will be collected over time to assess renal and bone biomarkers.

  30. Number of participants with abnormal renal and bone biomarkers - BIK [ Time Frame: At Months 6 and 12 ]
    Blood and urine samples will be collected over time to assess renal and bone biomarkers.

  31. Percentage of participants with Metabolic syndrome - OLI [ Time Frame: At Months 6 and 12 ]
    Metabolic syndrome is a cluster of conditions that occurs together increasing one's risk of heart disease, stroke and type 2 diabetes mellitus (DM). These conditions include increased blood pressure (BP), elevated blood glucose levels, excess body fat around the waist and abnormal fasting cholesterol and triglyceride (TG) levels.

  32. Percentage of participants with Metabolic syndrome - D2I [ Time Frame: At Months 5 and 11 ]
    Metabolic syndrome is a cluster of conditions that occurs together increasing one's risk of heart disease, stroke and type 2 DM. These conditions include increased BP, elevated blood glucose levels, excess body fat around the waist and abnormal fasting cholesterol and TG levels.

  33. Percentage of participants with Metabolic syndrome - BIK [ Time Frame: At Months 6 and 12 ]
    Metabolic syndrome is a cluster of conditions that occurs together increasing one's risk of heart disease, stroke and type 2 DM. These conditions include increased BP, elevated blood glucose levels, excess body fat around the waist and abnormal fasting cholesterol and TG levels.

  34. Number of participants with insulin resistance - OLI [ Time Frame: At Months 6 and 12 ]
    Insulin resistance will be assessed using homeostasis model of assessment-insulin resistance (HOMA-IR) Score.

  35. Number of participants with insulin resistance - D2I [ Time Frame: At Months 5 and 11 ]
    Insulin resistance will be assessed using HOMA-IR Score.

  36. Number of participants with insulin resistance -BIK [ Time Frame: At Months 6 and 12 ]
    Insulin resistance will be assessed using HOMA-IR Score.

  37. Percentage of participants with their treatment Preference as Assessed Using Preference Questionnaire - OLI [ Time Frame: At Month 12 ]
    The "Preference" questionnaire will include 3 questions and assess whether participants prefer the CAB LA + RPV LA injectable treatment or the daily oral ARV regimen, also evaluating the attributes supporting this preference.

  38. Percentage of participants with their Treatment Preference as Assessed Using Preference Questionnaire - D2I [ Time Frame: At Month 11 ]
    The "Preference" questionnaire will include 3 questions and assess whether participants prefer the CAB LA + RPV LA injectable treatment or the daily oral ARV regimen, also evaluating the attributes supporting this preference.

  39. Percentage of Participants with their treatment Preference as Assessed Using Preference Questionnaire - BIK [ Time Frame: At Month 12 ]
    The "Preference" questionnaire will include 3 questions and assess whether participants prefer the CAB LA + RPV LA injectable treatment or the daily oral ARV regimen, also evaluating the attributes supporting this preference.

  40. Change From Baseline in Total Treatment Satisfaction Score using HIV Treatment Satisfaction Status Questionnaire (HIVTSQs) (scores on a scale) - OLI [ Time Frame: Baseline (Day 1) and at Months 6 and 12 ]
    The HIVTSQs treatment satisfaction questionnaire comprises of 1-12 questions and the total treatment satisfaction score is computed with items 1-11 and summed to produce a score with a possible range of 0 to 66. Higher scores represent greater treatment satisfaction as compared to the past few weeks.

  41. Change From Baseline in Total Treatment Satisfaction Score using HIVTSQs (scores on a scale) - D2I [ Time Frame: Baseline (Day 1) and at Months 5 and 11 ]
    The HIVTSQs treatment satisfaction questionnaire comprises of 1-12 questions and the total treatment satisfaction score is computed with items 1-11 and summed to produce a score with a possible range of 0 to 66. Higher scores represent greater treatment satisfaction as compared to the past few weeks.

  42. Change From Baseline in Total Treatment Satisfaction Score using HIVTSQs (scores on a scale)- BIK [ Time Frame: Baseline (Day 1) and at Months 6 and 12 ]
    The HIVTSQs treatment satisfaction questionnaire comprises of 1-12 questions and the total treatment satisfaction score is computed with items 1-11 and summed to produce a score with a possible range of 0 to 66. Higher scores represent greater treatment satisfaction as compared to the past few weeks.

  43. Change From Baseline in individual item scores using HIVTSQs (scores on a scale) - OLI [ Time Frame: Baseline (Day 1) and at Months 6 and 12 ]
    HIVTSQs is a 12 item questionnaire. The individual item scores on HIVTSQs scale are rated as 6 (very satisfied, convenient, flexible, etc.) to 0 (very dissatisfied, inconvenient, inflexible, etc.). Higher scores represent greater satisfaction with each aspect of treatment.

  44. Change From Baseline in individual item scores using HIVTSQs (scores on a scale) - D2I [ Time Frame: Baseline (Day 1) and at Months 5 and 11 ]
    HIVTSQs is a 12 item questionnaire. The individual item scores on HIVTSQs scale are rated as 6 (very satisfied, convenient, flexible, etc.) to 0 (very dissatisfied, inconvenient, inflexible, etc.). Higher scores represent greater satisfaction with each aspect of treatment.

  45. Change From Baseline in individual item scores using HIVTSQs (scores on a scale) - BIK [ Time Frame: Baseline (Day 1) and at Months 6 and 12 ]
    HIVTSQs is a 12 item questionnaire. The individual item scores on HIVTSQs scale are rated as 6 (very satisfied, convenient, flexible, etc.) to 0 (very dissatisfied, inconvenient, inflexible, etc.). Higher scores represent greater satisfaction with each aspect of treatment.

  46. Number of participants with change in treatment satisfaction over time using the HIV Treatment Satisfaction Change Questionnaire (HIVTSQc)- OLI [ Time Frame: At Month 12 ]
    The HIVTSQc is a 1-12 items questionnaire. Each item is scored -3 to 3. Total treatment satisfaction change score is computed using items 1 to 11 and are summed to produce a score with a possible range of -33 to 33. Higher the score, greater the improvement in satisfaction with treatment; the lower the score, the greater the deterioration in satisfaction with treatment. A score of 0 will represent no change.

  47. Number of participants with change in treatment satisfaction over time using HIVTSQc - D2I [ Time Frame: At Month 11 ]
    The HIVTSQc is a 1-12 items questionnaire. Each item is scored -3 to 3. Total treatment satisfaction change score is computed using items 1 to 11 and are summed to produce a score with a possible range of -33 to 33. Higher the score, greater the improvement in satisfaction with treatment; the lower the score, the greater the deterioration in satisfaction with treatment. A score of 0 will represent no change.

  48. Number of participants with change in treatment satisfaction over time using HIVTSQc - BIK [ Time Frame: At Month 12 ]
    The HIVTSQc is a 1-12 items questionnaire. Each item is scored -3 to 3. Total treatment satisfaction change score is computed using items 1 to 11 and are summed to produce a score with a possible range of -33 to 33. Higher the score, greater the improvement in satisfaction with treatment; the lower the score, the greater the deterioration in satisfaction with treatment. A score of 0 will represent no change.

  49. Number of participants with change in Dimension Scores Using Perception of Injection (PIN) Questionnaire - OLI [ Time Frame: At Months 2, 6, and 12 ]
    The PIN questionnaire explores the bother of pain at the injection site and injection site reaction (ISRs), anxiety before and after injection, willingness to receive an HIV injectable treatment the following visit and satisfaction with the mode of treatment administration of individuals receiving injection and perceptions of individuals associated with receiving injections. This measure contains 21 items that measure pain at injection site, local site reactions, impact on functioning and willingness to pursue injectable treatment outside of a clinical trial. The items in the scale are rated on a 5-point scale and questions are phrased in such a way as to ensure that 1 is always equated with the most favorable perception of vaccination, and 5 is the most unfavorable.

  50. Number of participants with change in Dimension Scores Using PIN Questionnaire - D2I [ Time Frame: At Months 1, 5, and 11 ]
    The PIN questionnaire explores the bother of pain at the injection site and injection site reaction (ISRs), anxiety before and after injection, willingness to receive an HIV injectable treatment the following visit and satisfaction with the mode of treatment administration of individuals receiving injection and perceptions of individuals associated with receiving injections. This measure contains 21 items that measure pain at injection site, local site reactions, impact on functioning and willingness to pursue injectable treatment outside of a clinical trial. The items in the scale are rated on a 5-point scale and questions are phrased in such a way as to ensure that 1 is always equated with the most favorable perception of vaccination, and 5 is the most unfavorable.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Participants aged 18 years or older (or >=19 where required by local regulatory agencies), at the time of signing the informed consent.
  • A female participant is eligible to participate if she is not pregnant (as confirmed by a negative serum human chorionic gonadotropin (hCG) test at screen and a negative urine hCG test at Randomization), not lactating, and at least one of the following conditions applies.

    1. Non-reproductive potential defined as:

      • Pre-menopausal females with one of the following:

        1. Documented tubal ligation.
        2. Documented hysteroscopic tubal occlusion procedure with follow-up confirmation of bilateral tubal occlusion.
        3. Hysterectomy.
        4. Documented Bilateral Oophorectomy
      • Postmenopausal defined as 12 months of spontaneous amenorrhea (in questionable cases a blood sample with simultaneous follicle stimulating hormone [FSH] and estradiol levels consistent with menopause). Females on hormone replacement therapy (HRT) and whose menopausal status is in doubt will be required to use one of the highly effective contraception methods if they wish to continue their HRT during the study. Otherwise, they must discontinue HRT to allow confirmation of post-menopausal status prior to study enrolment.
    2. Reproductive potential and agrees to follow one of the options listed in the Modified List of Highly Effective Methods for Avoiding Pregnancy in Females of Reproductive Potential (FRP) from 30 days prior to the first dose of study medication, throughout the study, for at least 30 days after discontinuation of all oral study medications, and for at least 52 weeks after discontinuation of CAB LA and RPV LA.
  • Capable of giving signed informed consent, which includes compliance with the requirements and restrictions listed in the consent form and in this protocol. Eligible participants or their legal guardians (and next of kin when locally required), must sign a written Informed Consent Form before any protocol-specified assessments are conducted. Enrolment of participants who are unable to provide direct informed consent is optional and will be based on local legal/regulatory requirements and site feasibility to conduct protocol procedures.
  • Participants enrolled in France must be affiliated to, or a beneficiary of, a social security category.
  • Must be on the uninterrupted current regimen of BIK for at least 6 months prior to Screening with an undetectable HIV-1 viral load for at least 6 months prior to Screening. Only a single prior Integrase inhibitor (INI) regimen is allowed if BIK is a second line regimen >= 6 months prior to screening. Any prior change in regimen, defined as a change of a single drug or multiple drugs simultaneously, must have occurred due to tolerability/safety, access to medications, or convenience/simplification, and must not have been done for treatment failure (HIV-1 RNA >=400 c/mL).

Only a single prior INI regimen is permitted with the following limited exceptions

  • A change from Tenofovir disoproxil fumarate (TDF) to TAF will not be considered a regimen change.
  • Historical perinatal use of Nucleoside reverse transcriptase inhibitor (NRTI) when given in addition to an ongoing Highly active antiretroviral therapy (HAART) will not be considered a change in ART regimen.
  • The past use of ARVs in the context of Post Exposure Prophylaxis (PEP) or Pre-Exposure Prophylaxis (PrEP) while the participant was HIV negative will be allowed. Such cases will be evaluated on a case by case basis and may require documentation of HIV negative serology during time of PEP or PrEP.
  • A change in dosing scheme of the same drug from twice daily to once daily will not be considered a change in ART regimen if data support similar exposures and efficacy.
  • A change in formulation from multiple class regimens to single treatment regimens (of the same medications) would not be considered a change in ART regimen.

    • Documented evidence of plasma HIV-1 RNA measurements <50 c/mL in the 6 months prior to Screening.
    • Plasma HIV-1 RNA <50 c/mL at Screening.

Exclusion Criteria:

  • Within 6 months prior to Screening, any plasma HIV-1 RNA measurement >=50 c/mL.
  • Within the 6 to 12-month window prior to Screening, any plasma HIV-1 RNA measurement greater than (>)200 c/mL, or 2 or more plasma HIV-1 RNA measurements >=50 c/mL.
  • History of prior treatment failure to any Department of Health and Human Services (DHHS) recommended ART regimen.
  • History of drug holiday >1 month for any reason prior to Screening visit, except where all ART was stopped due to tolerability and/or safety concerns.
  • Any change to a second line regimen, defined as change of a single drug or multiple drugs simultaneously, due to virologic failure to therapy (defined as a confirmed plasma HIV 1 RNA measurement >=200 c/mL after initial suppression to <50 c/mL while on first line HIV therapy regimen).
  • Participants who are currently participating in or anticipate being selected for any other interventional study.
  • Women who are pregnant, breastfeeding or plan to become pregnant or breastfeed during the study.
  • Any evidence of a current Center for Disease Control and Prevention (CDC) Stage 3 disease except cutaneous Kaposi's sarcoma not requiring systemic therapy, and CD4+ counts <200 cells/mL are not exclusionary.
  • Participants with moderate to severe hepatic impairment.
  • Any pre-existing physical or mental condition (including substance use disorder) which, in the opinion of the Investigator, may interfere with the participant's ability to comply with the dosing schedule and/or protocol evaluations or which may compromise the safety of the participant.
  • Participants determined by the Investigator to have a high risk of seizures, including participants with an unstable or poorly controlled seizure disorder. A participant with a prior history of seizure may be considered for enrolment if the Investigator believes the risk of seizure recurrence is low. All cases of prior seizure history should be discussed with the Medical Monitor prior to enrolment.
  • All participants will be screened for syphilis.

    • Participants with untreated secondary (late latent) or tertiary syphilis infection, defined as a positive rapid plasma reagin (RPR) and a positive treponemal test without clear documentation of treatment, are excluded.
    • Participants with a false positive RPR (with negative treponemal test) or serofast RPR result (persistence of a reactive nontreponemal syphilis test despite history of adequate therapy and no evidence of re-exposure) may enroll after consultation with the Medical Monitor.
    • Participants with primary syphilis or early latent secondary syphilis (acquired within the preceding year) who have a positive RPR test and have not been treated may be treated during the screening period and if completion of antibiotic treatment occurs during the screening period, may be allowed entry after consultation with the Medical Monitor. If antibiotic treatment cannot be completed before the screening window ends, participants may be rescreened once following completion of antibiotic therapy for primary or early latent secondary syphilis.
  • Participants who, in the investigator's judgment, pose a significant suicide risk. Participant's recent history of suicidal behavior and/or suicidal ideation should be considered when evaluating for suicide risk.
  • The participant has a tattoo, gluteal implant/enhancements or other dermatological condition overlying the gluteus region which may interfere with interpretation of injection site reactions.
  • Evidence of Hepatitis B virus (HBV) infection based on the results of testing at Screening for Hepatitis B surface antigen (HBsAg), Hepatitis B core antibody (anti-HBc), Hepatitis B surface antibody (anti-HBs) and HBV DNA as follows:

    1. Participants positive for HBsAg are excluded.
    2. Participants negative for anti-HBs but positive for anti-HBc (negative HBsAg status), whether negative or positive for HBV DNA, are excluded.
  • Asymptomatic individuals with chronic hepatitis C virus (HCV) infection will not be excluded, however Investigators must carefully assess if therapy specific for HCV infection is required; participants who require or qualify for immediate HCV treatment are excluded for those co-infected participants who post entry into SOLAR decide treatment for HCV infection is warranted or desired either by the participant or by the treating physician.

Participants with HCV co-infection will be allowed entry into this study if:

  1. Liver enzymes meet entry criteria
  2. HCV Disease has undergone appropriate work-up, and is not advanced, and will not require treatment prior to the Month 14 visit. Additional information (where available) on participants with HCV co-infection at screening should include results from any liver biopsy, Fibroscan, ultrasound, or other fibrosis evaluation, history of cirrhosis or other decompensated liver disease, prior treatment, and timing/plan for HCV treatment.
  3. In the event that recent biopsy or imaging data is not available or inconclusive, the fibrosis (Fib)-4 score will be used to verify eligibility

i. Fib-4 score >3.25 is exclusionary ii. Fib-4 scores 1.45-3.25 requires Medical Monitor consultation

Fibrosis 4 Score Formula:

d. Age x aspartate aminotransferase (AST)/ Platelets x (square [Alanine aminotransferase {ALT}]).

  • Unstable liver disease (as defined by any of the following: presence of ascites, encephalopathy, coagulopathy, hypoalbuminemia, esophageal or gastric varices, or persistent jaundice or cirrhosis, or decompensated cirrhosis [for example {e.g.} ascites, encephalopathy, or variceal bleeding]), known biliary abnormalities (with the exception of Gilbert's syndrome or asymptomatic gallstones or otherwise stable chronic liver disease per investigator assessment).
  • History of liver cirrhosis with or without hepatitis viral co-infection.
  • Ongoing or clinically relevant pancreatitis
  • Clinically significant cardiovascular disease, as defined by history/evidence of congestive heart failure, symptomatic arrhythmia, angina/ischemia, coronary artery bypass grafting (CABG) surgery or percutaneous transluminal coronary angioplasty (PTCA) or any clinically significant cardiac disease.
  • Ongoing malignancy other than cutaneous Kaposi's sarcoma, basal cell carcinoma, or resected, non-invasive cutaneous squamous cell carcinoma, or cervical intraepithelial neoplasia; other localized malignancies require agreement between the investigator and the Study medical monitor for inclusion of the participant prior to randomization.
  • Any condition which, in the opinion of the Investigator, may interfere with the absorption, distribution, metabolism or excretion of the study drugs or render the participant unable to receive study medication.
  • History or presence of allergy or intolerance to the study drugs or their components or drugs of their class. In addition, if heparin is used during pharmacokinetic (PK) sampling, participants with a history of sensitivity to heparin or heparin-induced thrombocytopenia must not be enrolled.
  • Current or anticipated need for chronic anti-coagulation with the exception of the use of low dose acetylsalicylic acid (less than or equal to [<=]325 mg) or hereditary coagulation and platelet disorders such as hemophilia or Von Willebrand Disease.
  • Corrected QT interval (QTc [Bazett]) >450 milliseconds (msec) or QTc (Bazett) >480 msec for participants with bundle branch block.
  • Known or suspected active Coronavirus Disease-2019 (COVID-19) infection or has had contact with an individual with known COVID-19, within 14 days of study enrolment.
  • Known or suspected presence of resistance mutations as defined by the International Antiviral Society-United Sates of America (IAS-USA) resistance guidelines to the individual components of BIK (BIC, FTC, TAF), RPV, and CAB by any historical resistance test result.
  • Any verified Grade 4 laboratory abnormality. A single repeat test is allowed during the Screening phase to verify a result.
  • Any acute laboratory abnormality at Screening, which, in the opinion of the investigator, would preclude the participant's participation in the study of an investigational compound.
  • Participant has estimated creatine clearance <30mL/minute per 1.73 meter square (m^2) via Chronic Kidney Disease-Epidemiology Collaboration (CKD-EPI) Method.
  • ALT >=3 times upper limit of normal (ULN).
  • Exposure to an experimental drug or experimental vaccine within either 30 days, 5 half-lives of the test agent, or twice the duration of the biological effect of the test agent, whichever is longer, prior to Day 1 of this study.
  • Treatment with any of the following agents within 28 days of Screening:

    • radiation therapy;
    • cytotoxic chemotherapeutic agents;
    • tuberculosis therapy with the exception of isoniazid (isonicotinylhydrazid/INH);
    • anti-coagulation agents;
    • Immunomodulators that alter immune responses such as chronic systemic corticosteroids, interleukins, or interferons.
  • Treatment with an HIV-1 immunotherapeutic vaccine within 90 days of Screening.
  • Treatment with any agent, except recognized ART as allowed above, with documented activity against HIV-1 within 28 days of study Day 1. Treatment with acyclovir/valacyclovir is permitted.
  • Use of medications which are associated with Torsade de Pointes.
  • Participants receiving any prohibited medication and who are unwilling or unable to switch to an alternate medication.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04542070


Contacts
Layout table for location contacts
Contact: US GSK Clinical Trials Call Center 877-379-3718 GSKClinicalSupportHD@gsk.com
Contact: EU GSK Clinical Trials Call Center +44 (0) 20 89904466 GSKClinicalSupportHD@gsk.com

Locations
Show Show 73 study locations
Sponsors and Collaborators
ViiV Healthcare
Janssen, LP
Investigators
Layout table for investigator information
Study Director: GSK Clinical Trials ViiV Healthcare
Layout table for additonal information
Responsible Party: ViiV Healthcare
ClinicalTrials.gov Identifier: NCT04542070    
Other Study ID Numbers: 213500
First Posted: September 9, 2020    Key Record Dates
Last Update Posted: January 27, 2021
Last Verified: January 2021
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Yes
Plan Description: IPD for this study will be made available via the Clinical Study Data Request site.
Supporting Materials: Study Protocol
Statistical Analysis Plan (SAP)
Informed Consent Form (ICF)
Clinical Study Report (CSR)
Time Frame: IPD will be made available within 6 months of publishing the results of the primary endpoints, key secondary endpoints and safety data of the study
Access Criteria: Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension can be granted, when justified, for up to another 12 months.
URL: http://clinicalstudydatarequest.com

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by ViiV Healthcare:
HIV
Cabotegravir
Rilpivirine
BIKTARVY
Antiretroviral therapy
Additional relevant MeSH terms:
Layout table for MeSH terms
HIV Infections
Lentivirus Infections
Retroviridae Infections
RNA Virus Infections
Virus Diseases
Sexually Transmitted Diseases, Viral
Sexually Transmitted Diseases
Immunologic Deficiency Syndromes
Immune System Diseases
Rilpivirine
Reverse Transcriptase Inhibitors
Nucleic Acid Synthesis Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Anti-Retroviral Agents
Antiviral Agents
Anti-Infective Agents
Anti-HIV Agents